ZDHHC13

Across TCGA pan-cancer cohorts, ZDHHC13 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ZDHHC13’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where ZDHHC13 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZDHHC13 is over-expressed in tumor, although a few such as THCA and HNSC show the opposite, repressed pattern.

BRCA, LUSC, and LUAD are the cancer types where ZDHHC13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZDHHC13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	+0.952	<.001	8	view →
LUSC	Female	All	+1.038	<.001	7	view →
LUAD	Male	All	+0.878	<.001	7	view →
THCA	Male	All	−0.314	<.001	6	view →
CHOL	Female	All	+3.070	<.001	5	view →
STAD	All	All	+0.750	.007	4	view →
LIHC	Female	All	+0.652	<.001	4	view →
BLCA	Male	III,IV	+1.631	.025	2	view →
PAAD	All	All	+0.602	.033	2	view →
HNSC	All	II,III,IV	−0.432	.028	2	view →
KIRP	All	II,III,IV	+0.460	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ZDHHC13–BRCA

Open the BRCA breakdown →